Terns Pharmaceuticals receives FDA breakthrough status for TERN-701 leukemia treatment
Updated
Updated · MarketWatch · Apr 27
Terns Pharmaceuticals receives FDA breakthrough status for TERN-701 leukemia treatment
13 articles · Updated · MarketWatch · Apr 27
The FDA granted breakthrough therapy designation to TERN-701 for treating adults with Ph+ chronic myeloid leukemia, based on interim phase 1/2 trial data.
The designation aims to expedite TERN-701's development and review, following encouraging major and deep molecular response rates at 24 weeks.
Breakthrough therapy status is reserved for drugs addressing serious conditions with promising early results, potentially accelerating Terns Pharmaceuticals' path to market approval.
How does TERN-701's unique mechanism give it an edge over existing leukemia drugs?
Could TERN-701 finally make treatment-free remission a reality for more CML patients?
Is Merck's $6.7 billion bet on TERN-701 a stroke of genius or a costly gamble?
Does fast-tracking drugs via Breakthrough Designation compromise long-term safety for speed?
A rival bidder withdrew. What hidden risks does this new leukemia drug pose for Merck?